Immix Biopharma (IMMX) Capital Expenditures (2021 - 2026)

Immix Biopharma has disclosed Capital Expenditures across 5 years of filings, most recently posting $32486.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $32486.0, down 52.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $697698.0 (down 26.05% YoY), and the FY2025 annual result was $732925.0, down 37.77% from the prior year.
• Capital Expenditures came in at $32486.0 for Q1 2026 at Immix Biopharma, down from $165126.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $507151.0 in Q4 2024 to a low of $13177.0 in Q4 2023.
• The 4-year median for Capital Expenditures is $146378.0 (2025), against an average of $195626.8.
• Across the five-year window, Capital Expenditures jumped 3748.76% in 2024 and sank 77.57% in 2025, its largest moves.
• Immix Biopharma's Capital Expenditures stood at $13177.0 in 2023, then surged by 3748.76% to $507151.0 in 2024, then slumped by 67.44% to $165126.0 in 2025, then sank by 80.33% to $32486.0 in 2026.
• The last three Capital Expenditures figures came in at $32486.0 (Q1 2026), $165126.0 (Q4 2025), and $372456.0 (Q3 2025), per Business Quant data.